Presentation Resources
American College of Obstetrics & Gynecology. (2017). Opioid Use and Opioid Use Disorder in Pregnancy.
Behnke, M., Smith, V. C., & Committee on Substance Abuse. (2013). Prenatal substance abuse: Short-
Ecker, J. et al. (2019). Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists
https://www.ajog.org/article/S0002-9378(19)30500-9/fulltext
Friedman, S., Heneghan, A. & Rosenthal, M. (2009). Characteristics of women who do not seek prenatal care and implications for prevention. JOGNN, 38 (2), 174-181.
Summary only at https://www.jognn.org/article/S0884-2175(15)30172-6/abstract
Jones, H. et al. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine, 363(24), 2320- 2331.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073631/
Jones HE, Fischer G, Heil SH, et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) – Approach, Issues, and Lessons Learned.
Kelty, C.V. & Hulse, G. (2017). A Retrospective Cohort Study of Birth Outcomes...
Summary at https://pubmed.ncbi.nlm.nih.gov/28536981/
Milliren, C. E., Gupta, M., Graham, D. A., Melvin, P., Jorina, M., & Ozonoff, A. (2017). Hospital variation in neonatal abstinence syndrome incidence, treatment modalities, resource use, and costs across pediatric hospitals in the United States, 2013 to 2
Abstract only
Mitchell MM, Severtson SG, Latimer WW. Pregnancy and race/ethnicity as predictors of motivation for drug treatment. American Journal of Drug and Alcohol Abuse. 2008; 34(4): 397-404.
McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000 Oct 4;284(13):1689-95. doi: 10.1001/jama.284.13.1689. PMID: 11015800
Abstract only
Mullins, N. et al. (2019). Buprenorphine and Naloxone versus Buprenorphine for opioid use disorder in pregnancy: A cohort study
Summary only at https://pubmed.ncbi.nlm.nih.gov/31567599/
Neonatal Abstinence Syndrome Among Michigan Infants (2016)
Ross, E., Graham, D., Money, K., & Stanwood, G. (2015). Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology, 40 (1), 61–87.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262892/
SAMHSA. (2018). Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorders and Their Infants.
https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdf
SAMHSA TIP 63: Medications for Opioid Use Disorder - Full Document
Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol. 2020 Jan;222(1):83.e1-83.e8. doi: 10.1016/j.ajog.2019.07.037.
Summary at https://pubmed.ncbi.nlm.nih.gov/31376396/
Tsai, L. C., & Doan, T. J. (2016). Breastfeeding among mothers on opioid maintenance treatment: A literature review. Journal of Human Lactation, 32(3), 521–529.
Abstract only at https://doi.org/10.1177/0890334416641909
Wong, J et al. (2018).Does maternal buprenorphine dose affect severity or incidence of neonatal abstinence syndrome?Journal of Addiction Medicine, 12(6), 435-441.
Summary only at https://pubmed.ncbi.nlm.nih.gov/29905586/
Children and Family Futures, 2017
Related Resources
Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study. Summary only:
https://europepmc.org/article/med/31567599